Terms: = Ovarian cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
30 results:
1. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
2. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
3. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
4. Expression and purification of recombinant human CCL5 and its biological characterization.
Ma Z; Zhang J; Wang L; Liu Y; Wang Y; Liu W; Xing G; Cheng K; Zheng W; Xiang L
Protein J; 2022 Apr; 41(2):337-344. PubMed ID: 35524873
[TBL] [Abstract] [Full Text] [Related]
5. Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological cancer Harboring RAS Mutation: A Case Series.
Niogret J; Derangère V; Richard C; Nuttin L; Ghiringhelli F; Favier L; Lefevre LB; Bergeron A; Arnould L; Boidot R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328764
[TBL] [Abstract] [Full Text] [Related]
6. New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
[TBL] [Abstract] [Full Text] [Related]
7. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of ovarian cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract] [Full Text] [Related]
8. Multiomics Characterization of Low-Grade Serous ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract] [Full Text] [Related]
9. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
[TBL] [Abstract] [Full Text] [Related]
10. Malignant struma ovarii: next-generation sequencing of six cases revealed nras, Braf, and Jak3 mutations.
Poli R; Scatolini M; Grosso E; Maletta F; Gallo M; Liscia D; Nelva A; Cesario F; Forte G; Metovic J; Volante M; Arvat E; Papotti M
Endocrine; 2021 Jan; 71(1):216-224. PubMed ID: 32743766
[TBL] [Abstract] [Full Text] [Related]
11. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
[TBL] [Abstract] [Full Text] [Related]
12. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract] [Full Text] [Related]
13. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract] [Full Text] [Related]
14. Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.
Zhang L; Luo M; Yang H; Zhu S; Cheng X; Qing C
J Ovarian Res; 2019 Feb; 12(1):19. PubMed ID: 30786925
[TBL] [Abstract] [Full Text] [Related]
15. A rare case of synchronous ovarian tumors: clinical case report and literature review.
Roşu GA; Furău GO; Ionescu CA; Dimitriu MCT; Neacşu A; Ioan RG; Călin FD; Matei A; Bănacu M; Popescu I; Gheorghiu D; Neacşu I; Bacalbaşa N; Furău CG
Rom J Morphol Embryol; 2019; 60(4):1365-1370. PubMed ID: 32239119
[TBL] [Abstract] [Full Text] [Related]
16. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract] [Full Text] [Related]
17. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract] [Full Text] [Related]
18. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract] [Full Text] [Related]
19. Malignant struma ovarii harboring a unique nras mutation: case report and review of the literature.
Gobitti C; Sindoni A; Bampo C; Baresic T; Giorda G; Alessandrini L; Canzonieri V; Franchin G; Borsatti E
Hormones (Athens); 2017 Jul; 16(3):322-327. PubMed ID: 29278520
[TBL] [Abstract] [Full Text] [Related]
20. The levels of mutant K-RAS and mutant n-ras are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
[TBL] [Abstract] [Full Text] [Related]
[Next]